Prostacyclin improves transcoronary myocardial delivery of adipose tissue-derived stromal cells.
Prostacyclin improves transcoronary myocardial delivery of adipose tissue-derived stromal cells.
复制标题
前列环素可改善脂肪组织来源的基质细胞的经冠状动脉心肌输送。
DOI：
10.1093/eurheartj/ehl154
复制
发表时间：
2006
影响因子：
39.3
通讯作者：
DeCaterina,Raffaele
中科院分区：
文献类型：
--
作者：
Madonna,Rosalinda;Rinaldi,Lucia;Rossi,Cosmo;Geng,Yong-Jian;DeCaterina,Raffaele
脂肪组织来源的基质细胞（ADSCs）心脏移植作为心脏修复的治疗方法正在评估中。前列环素（PGI 2）是一种血管扩张剂，对血小板聚集和血细胞粘附具有额外的作用，具有心脏保护作用，可能有利于ADSC的心肌递送。我们研究了植入和影响心脏功能的transcoronary交付的脂肪干细胞和PGI 2的效果相比，硝酸甘油（NTG）和腺苷（Ado）在离体灌流小鼠hearts.Methods和resultsInfusion的脂肪干细胞在<1× 106细胞/mL的收缩性和节律没有引起显着的变化，而较高的细胞剂量引起心功能不全。灌注PGI 2，NTG和Ado浓度依赖性地增加冠状动脉流量（CF）。与NTG和Ado不同的PGI 2灌注增加了ADSC的递送和进入心肌内膜，而不影响心室或代谢功能和CF（移植的ADSC，作为对照的百分比，在产生50%最大血管舒张的剂量下：PGI 2：220±12，P<0.001; NTG：110±8，P=N.S.; Ado：80±5，P=N.S.）。结论PGI 2可安全地增加ADSCs的心肌输送，其作用机制与其血管舒张特性无关，可能用于心脏修复的细胞治疗。
AimsHeart transplantation of adipose tissue-derived stromal cells (ADSCs) is under evaluation as a therapy for cardiac repair. Prostacyclin (PGI2), a vasodilator with additional effects on platelet aggregation and blood cell adhesion, exerts cardioprotection and might favour the myocardial delivery of ADSCs. We investigated the engraftment and influence on cardiac function of the transcoronary delivery of ADSCs and the effects of PGI2compared with nitroglycerin (NTG) and adenosine (Ado) in isolated–perfused mouse hearts.Methods and resultsInfusion of ADSCs at <1×106cells/mL caused no significant changes in contractility and rhythm, whereas higher cell doses caused cardiac dysfunction. Perfusion with PGI2, NTG, and Ado concentration-dependently increased coronary flow (CF). Perfusion with PGI2, at variance from NTG and Ado, increased ADSC delivery and entrance into the myocardial interstitium without affecting ventricular or metabolic functions and CF (engrafted ADSCs, as percentage of control, at doses producing 50% of maximum vasodilation: PGI2: 220±12,P<0.001; NTG: 110±8,P=N.S.; Ado: 80±5,P=N.S.).ConclusionPGI2safely increases myocardial delivery of ADSCs, by mechanisms independent of its vasodilatory properties, with a potential for its use in cell therapy for cardiac repair.